FDA Clears Registrational TEMPO-1 Study of CRB-701

Company Corbus Pharmaceuticals Event Type Regulatory Clearance (FDA, Registrational Randomized Trial) Modality Antibody-drug conjugate (nectin-4-directed, MMAE payload) Asset CRB-701 Target Nectin-4 Disease Area Second-line oropharyngeal cancer Summary FDA cleared Corbus Pharmaceuticals to initiate TEMPO-1, a 250-patient randomized registrational study of CRB-701 in second-line oropharyngeal cancer.…